Home / Late toxicity and quality of life from GETUG-AFU 22 study: A randomized phase II trial comparing 6 months of degarelix in combination with radiotherapy to radiotherapy alone for patients with detectable PSA after radical prostatectomy
Late toxicity and quality of life from GETUG-AFU 22 study: A randomized phase II trial comparing 6 months of degarelix in combination with radiotherapy to radiotherapy alone for patients with detectable PSA after radical prostatectomy
Sargos P.,
Guerif S.,
Fraisse J.,
Meyer E.,
Supiot S.,
Lagneau E.,
Deniaud-Alexandre E.,
Rochin P.,
Benyoucef A.,
Cartier L.,
Hamidou H.,
Hasbini A.,
Crehange G.,
Pommier P.,
De Laroche G.,
Pelissier S.,
Gross E.,
Fourneret P.,
Salomon L.,
Latorzeff I.
This website uses cookies to improve user experience. By using our website you consent to all cookies in accordance with our Privacy Policy.